

**Blood and DNA Available to ASs
3/6/2013**

Blood Collection Timepoints:

Baseline: All Clinical Trial (CT) and Observational Study (OS) participants

Year One: Clinical Trial participants

Year Three: Observational Study participants; Clinical Trial subsample (see description of CT blood collection subsample)

Year Six: Clinical Trial subsample

Year Nine: Clinical Trail subsample

Year ~18: WHI Long Life Study participants (N~8,000; collected between 2/2012 and 2/2013)

CT SUMMARY (Any Main Outcome)											
	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
Visit	Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	12959	190	EDTA	1607	12%	420	3%	1604	12%	9328	72%
AV1	12214	897	EDTA	2192	18%	80	1%	879	7%	9237	76%
Baseline	12959	65	Serum	328	3%	141	1%	535	4%	11955	92%
AV1	12214	755	Serum	970	8%	33	0%	165	1%	11188	92%
Baseline	12959	131	Citrate	1666	13%	422	3%	231	2%	10640	82%
AV1	12214	826	Citrate	2183	18%	137	1%	176	1%	9895	81%

OS SUMMARY (Any Main Outcome)											
	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
Visit	Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	16595	340	EDTA	2178	13%	1525	9%	3467	21%	9425	57%
AV3	12796	2268	EDTA	2524	20%	61	0%	739	6%	10012	78%
Baseline	16595	56	Serum	961	6%	449	3%	1014	6%	14171	85%
AV3	12796	2054	Serum	2200	17%	1	0%	12	0%	11111	87%
Baseline	16595	193	Citrate	1049	6%	772	5%	1775	11%	12999	78%
AV3	12795	2149	Citrate	2463	19%	7	0%	36	0%	10835	85%

*Participants with no draw included in 0 volume column

** Total number of participants whose first occurrence of an outcome occurred on or after the first visit

CT Blood Remaining by Outcome for ASs
3/6/13

- Outcomes as of March 2011
- (R*) in the outcome name indicates a rollup outcome. Rollup outcomes combine several non rollup outcomes together (e.g. breast cancer (R*) combines breast cancer and breast cancer deaths)
- *Participants with no draw included in 0 volume column
- ** Total number of participants whose first occurrence of an outcome occurred on or after the first visit

EDTA PLASMA - CT blood remaining by Outcome

Visit	Outcome	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
		Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	Cancer, Breast Cancer (R*)	4253	61	EDTA	360	8%	25	1%	921	22%	2947	69%
	Cancer, Breast Cancer Invasive (R*)	3450	49	EDTA	289	8%	24	1%	892	26%	2245	65%
	Cancer, Colorectal Cancer (R*)	1094	19	EDTA	107	10%	15	1%	396	36%	576	53%
	Cancer, Endometrial Cancer (R*)	578	7	EDTA	51	9%	8	1%	21	4%	498	86%
	Cancer, Ovarian Cancer (R*)	370	2	EDTA	42	11%	3	1%	13	4%	312	84%
	Cardio, CHD (R*)	3586	53	EDTA	575	16%	115	3%	224	6%	2672	75%
	Cardio, Clinical MI	2700	44	EDTA	437	16%	100	4%	165	6%	1998	74%
	Cardio, Stroke (R*)	2816	43	EDTA	510	18%	310	11%	154	5%	1842	65%
	Fracture, Hip Fracture	1704	23	EDTA	186	11%	24	1%	125	7%	1369	80%
AV1	Cancer, Breast Cancer (R*)	4052	265	EDTA	577	14%	8	0%	836	21%	2646	65%
	Cancer, Breast Cancer Invasive (R*)	3292	225	EDTA	485	15%	7	0%	833	25%	1982	60%
	Cancer, Colorectal Cancer (R*)	1015	75	EDTA	164	16%	1	0%	19	2%	833	82%
	Cancer, Endometrial Cancer (R*)	538	30	EDTA	73	14%	4	1%	10	2%	454	84%
	Cancer, Ovarian Cancer (R*)	350	23	EDTA	60	17%	1	0%	3	1%	286	82%
	Cardio, CHD (R*)	3371	295	EDTA	741	22%	66	2%	66	2%	2517	75%
	Cardio, Clinical MI	2519	202	EDTA	541	21%	52	2%	53	2%	1892	75%
	Cardio, Stroke (R*)	2675	201	EDTA	605	23%	8	0%	47	2%	2025	76%
	Fracture, Hip Fracture	1654	109	EDTA	256	15%	7	0%	33	2%	1362	82%

SERUM - CT blood remaining by Outcome

Visit	Outcome	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
		Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	Cancer, Breast Cancer (R*)	4253	17	Serum	96	2%	47	1%	181	4%	3929	92%
	Cancer, Breast Cancer Invasive (R*)	3450	12	Serum	81	2%	46	1%	162	5%	3161	92%
	Cancer, Colorectal Cancer (R*)	1094	3	Serum	31	3%	21	2%	88	8%	954	87%
	Cancer, Endometrial Cancer (R*)	578	5	Serum	18	3%	1	0%	10	2%	549	95%
	Cancer, Ovarian Cancer (R*)	370	1	Serum	10	3%			11	3%	349	94%
	Cardio, CHD (R*)	3586	20	Serum	111	3%	46	1%	158	4%	3271	91%
	Cardio, Clinical MI	2700	17	Serum	84	3%	37	1%	121	4%	2458	91%
	Cardio, Stroke (R*)	2816	18	Serum	77	3%	32	1%	115	4%	2592	92%
	Fracture, Hip Fracture	1704	10	Serum	48	3%	14	1%	66	4%	1576	92%
AV1	Cancer, Breast Cancer (R*)	4052	221	Serum	279	7%	18	0%	76	2%	3684	91%
	Cancer, Breast Cancer Invasive (R*)	3292	193	Serum	243	7%	17	1%	72	2%	2965	90%
	Cancer, Colorectal Cancer (R*)	1015	64	Serum	87	9%	2	0%	16	2%	910	90%
	Cancer, Endometrial Cancer (R*)	538	27	Serum	38	7%	1	0%	1	0%	499	93%
	Cancer, Ovarian Cancer (R*)	350	18	Serum	23	7%			1	0%	326	93%
	Cardio, CHD (R*)	3371	253	Serum	313	9%	12	0%	40	1%	3006	89%
	Cardio, Clinical MI	2519	166	Serum	215	9%	6	0%	31	1%	2267	90%
	Cardio, Stroke (R*)	2675	167	Serum	213	8%	4	0%	49	2%	2413	90%
	Fracture, Hip Fracture	1654	88	Serum	122	7%	4	0%	18	1%	1512	91%

CITRATE PLASMA - CT blood remaining by Outcome

Visit	Outcome	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
					Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt
Baseline	Cancer, Breast Cancer (R*)	4253	32	Citrate	348	8%	17	0%	36	1%	3852	91%
	Cancer, Breast Cancer Invasive (R*)	3450	25	Citrate	285	8%	14	0%	31	1%	3120	90%
	Cancer, Colorectal Cancer (R*)	1094	10	Citrate	102	9%	5	0%	23	2%	964	88%
	Cancer, Endometrial Cancer (R*)	578	6	Citrate	54	9%	3	1%	2	0%	519	90%
	Cancer, Ovarian Cancer (R*)	370	5	Citrate	42	11%	1	0%			327	88%
	Cardio, CHD (R*)	3586	34	Citrate	605	17%	92	3%	72	2%	2817	79%
	Cardio, Clinical MI	2700	26	Citrate	463	17%	71	3%	53	2%	2113	78%
	Cardio, Stroke (R*)	2816	40	Citrate	583	21%	359	13%	122	4%	1752	62%
	Fracture, Hip Fracture	1704	20	Citrate	190	11%	18	1%	22	1%	1474	87%
AV1	Cancer, Breast Cancer (R*)	4052	229	Citrate	539	13%	8	0%	31	1%	3491	86%
	Cancer, Breast Cancer Invasive (R*)	3292	197	Citrate	455	14%	6	0%	23	1%	2825	86%
	Cancer, Colorectal Cancer (R*)	1015	68	Citrate	161	16%	4	0%	11	1%	842	83%
	Cancer, Endometrial Cancer (R*)	538	32	Citrate	75	14%			2	0%	463	86%
	Cancer, Ovarian Cancer (R*)	350	19	Citrate	56	16%					294	84%
	Cardio, CHD (R*)	3371	282	Citrate	745	22%	58	2%	46	1%	2541	75%
	Cardio, Clinical MI	2519	192	Citrate	548	22%	40	2%	34	1%	1916	76%
	Cardio, Stroke (R*)	2675	185	Citrate	653	24%	78	3%	101	4%	1858	69%
	Fracture, Hip Fracture	1654	101	Citrate	253	15%	12	1%	21	1%	1372	83%

OS Blood Remaining by Outcome for ASs
3/6/13

- Outcomes as of March 2011
- (R*) in the outcome name indicates a rollup outcome. Rollup outcomes combine several non rollup outcomes together (e.g. breast cancer (R*) combines breast cancer and breast cancer deaths)
- *Participants with no draw included in 0 volume column
- ** Total number of participants whose first occurrence of an outcome occurred on or after the first visit

EDTA PLASMA - OS blood remaining by Outcome												
Visit	Outcome	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
		Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	Cancer, Breast Cancer (R*)	6095	123	EDTA	393	6%	174	3%	500	8%	5028	82%
	Cancer, Breast Cancer Invasive (R*)	5059	106	EDTA	327	6%	141	3%	409	8%	4182	83%
	Cancer, Colorectal Cancer (R*)	1328	35	EDTA	540	41%	264	20%	295	22%	229	17%
	Cancer, Endometrial Cancer (R*)	835	19	EDTA	69	8%	26	3%	78	9%	662	79%
	Cancer, Ovarian Cancer (R*)	557	6	EDTA	36	6%	16	3%	40	7%	465	83%
	Cardio, CHD (R*)	4134	99	EDTA	506	12%	816	20%	2265	55%	547	13%
	Cardio, Clinical MI	3093	78	EDTA	402	13%	652	21%	1655	54%	384	12%
	Cardio, Stroke (R*)	3264	60	EDTA	814	25%	423	13%	468	14%	1559	48%
	Fracture, Hip Fracture	2202	47	EDTA	202	9%	109	5%	340	15%	1551	70%
AV3	Cancer, Breast Cancer (R*)	4491	631	EDTA	716	16%	10	0%	100	2%	3686	82%
	Cancer, Breast Cancer Invasive (R*)	3719	534	EDTA	600	16%	10	0%	92	2%	3036	82%
	Cancer, Colorectal Cancer (R*)	996	174	EDTA	198	20%	14	1%	66	7%	721	72%
	Cancer, Endometrial Cancer (R*)	621	92	EDTA	104	17%	1	0%	6	1%	513	83%
	Cancer, Ovarian Cancer (R*)	421	75	EDTA	80	19%			3	1%	339	81%
	Cardio, CHD (R*)	3382	656	EDTA	719	21%	33	1%	525	16%	2116	63%
	Cardio, Clinical MI	2452	402	EDTA	451	18%	28	1%	419	17%	1565	64%
	Cardio, Stroke (R*)	2682	510	EDTA	564	21%	2	0%	93	3%	2028	76%
	Fracture, Hip Fracture	1908	325	EDTA	364	19%	7	0%	82	4%	1461	77%

SERUM - OS blood remaining by Outcome												
Visit	Outcome	Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
		Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	Cancer, Breast Cancer (R*)	6095	19	Serum	182	3%	95	2%	310	5%	5508	90%
	Cancer, Breast Cancer Invasive (R*)	5059	17	Serum	159	3%	87	2%	288	6%	4525	89%
	Cancer, Colorectal Cancer (R*)	1328	5	Serum	127	10%	116	9%	278	21%	807	61%
	Cancer, Endometrial Cancer (R*)	835	9	Serum	162	19%	83	10%	122	15%	468	56%
	Cancer, Ovarian Cancer (R*)	557	1	Serum	78	14%	39	7%	63	11%	377	68%
	Cardio, CHD (R*)	4134	17	Serum	327	8%	66	2%	150	4%	3591	87%
	Cardio, Clinical MI	3093	13	Serum	261	8%	53	2%	120	4%	2659	86%
	Cardio, Stroke (R*)	3264	4	Serum	134	4%	48	1%	98	3%	2984	91%
	Fracture, Hip Fracture	2202	7	Serum	162	7%	89	4%	165	7%	1786	81%
AV3	Cancer, Breast Cancer (R*)	4489	560	Serum	616	14%			3	0%	3886	87%
	Cancer, Breast Cancer Invasive (R*)	3719	480	Serum	531	14%			3	0%	3200	86%
	Cancer, Colorectal Cancer (R*)	996	162	Serum	175	18%			4	0%	819	82%
	Cancer, Endometrial Cancer (R*)	622	86	Serum	92	15%					531	85%
	Cancer, Ovarian Cancer (R*)	421	72	Serum	75	18%					347	82%
	Cardio, CHD (R*)	3381	602	Serum	640	19%			5	0%	2745	81%
	Cardio, Clinical MI	2451	365	Serum	395	16%			5	0%	2060	84%
	Cardio, Stroke (R*)	2682	452	Serum	488	18%	1	0%	2	0%	2197	82%
	Fracture, Hip Fracture	1909	294	Serum	309	16%					1605	84%

CITRATE PLASMA - OS blood remaining by Outcome												
		Total**	No	Blood	0*		>0 - <.5		.5 - <1		1 - <1.5	
Visit	Outcome	Ppts	Draw*	Type	Ppt	%	Ppt	%	Ppt	%	Ppt	%
Baseline	Cancer, Breast Cancer (R*)	6095	67	Citrate	231	4%	91	1%	367	6%	5406	89%
	Cancer, Breast Cancer Invasive (R*)	5059	59	Citrate	197	4%	82	2%	320	6%	4460	88%
	Cancer, Colorectal Cancer (R*)	1328	15	Citrate	63	5%	36	3%	162	12%	1067	80%
	Cancer, Endometrial Cancer (R*)	835	10	Citrate	29	3%	17	2%	79	9%	710	85%
	Cancer, Ovarian Cancer (R*)	557	4	Citrate	19	3%	16	3%	470	84%	52	9%
	Cardio, CHD (R*)	4134	64	Citrate	380	9%	128	3%	316	8%	3310	80%
	Cardio, Clinical MI	3093	50	Citrate	308	10%	101	3%	258	8%	2426	78%
	Cardio, Stroke (R*)	3264	35	Citrate	385	12%	600	18%	524	16%	1755	54%
	Fracture, Hip Fracture	2202	24	Citrate	116	5%	45	2%	152	7%	1889	86%
	AV3	Cancer, Breast Cancer (R*)	4489	594	Citrate	694	15%	2	0%	4	0%	3818
Cancer, Breast Cancer Invasive (R*)		3719	505	Citrate	590	16%	2	0%	3	0%	3149	85%
Cancer, Colorectal Cancer (R*)		996	165	Citrate	187	19%	1	0%	9	1%	802	81%
Cancer, Endometrial Cancer (R*)		622	90	Citrate	107	17%	1	0%			520	84%
Cancer, Ovarian Cancer (R*)		421	74	Citrate	79	19%					342	81%
Cardio, CHD (R*)		3381	628	Citrate	750	22%			6	0%	2637	78%
Cardio, Clinical MI		2451	383	Citrate	481	20%			6	0%	1976	81%
Cardio, Stroke (R*)		2682	474	Citrate	538	20%	1	0%	3	0%	2147	80%
Fracture, Hip Fracture		1908	311	Citrate	340	18%	3	0%	17	1%	1554	81%

DNA Available for Ancillary Studies
3/6/13

DNA CT				
Outcome (as of March 2011)	Ppts	DNA	No DNA, Has Buffy	None
Breast Cancer	4053	3625 (89%)	366 (9%)	62 (2%)
Breast Cancer - Invasive	3278	3140 (96%)	92 (3%)	46 (1%)
CHD	3490	3219 (92%)	201 (6%)	70 (2%)
Colorectal Cancer	1077	997 (93%)	65 (6%)	15 (1%)
Endometrial Cancer	558	506 (91%)	42 (8%)	10 (2%)
Fracture (general)	9484	6899 (73%)	2431 (26%)	154 (2%)
Fracture - Hip	1606	1496 (93%)	70 (4%)	40 (2%)
MI	2615	2447 (94%)	118 (5%)	50 (2%)
Renal Cancer	23	21 (91%)	2 (9%)	0 (0%)
Stroke	2679	2541 (95%)	97 (4%)	41 (2%)

DNA OS				
Outcome (as of March 2011)	Ppts	DNA	No DNA, Has Buffy	None
Breast Cancer	5848	5216 (89%)	572 (10%)	60 (1%)
Breast Cancer - Invasive	4853	4617 (96%)	181 (4%)	55 (1%)
CHD	4122	4038 (92%)	31 (1%)	53 (1%)
Colorectal Cancer	1308	1269 (93%)	19 (1%)	20 (2%)
Endometrial Cancer	804	741 (91%)	55 (7%)	8 (1%)
Fracture (general)	2921	2699 (73%)	193 (7%)	29 (1%)
Fracture - Hip	2194	2049 (93%)	121 (6%)	24 (1%)
MI	3078	3023 (94%)	22 (1%)	33 (1%)
Renal Cancer	36	33 (91%)	3 (8%)	0 (0%)
Stroke	3233	3024 (95%)	167 (5%)	42 (1%)